Challenges in solid organ transplantation in people living with HIV

Intensive Care Medicine, Jan 2019

Jose M. Miro, Paolo A. Grossi, Christine M. Durand

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

Challenges in solid organ transplantation in people living with HIV

Intensive Care Medicine pp 1–3 | Cite as Challenges in solid organ transplantation in people living with HIV AuthorsAuthors and affiliations Jose M. MiroPaolo A. GrossiChristine M. Durand Editorial First Online: 14 January 2019 1 Shares 233 Downloads Electronic supplementary material The online version of this article ( contains supplementary material, which is available to authorized users. Combined antiretroviral therapy (ART) has made HIV infection a manageable chronic disease, allowing a near normal lifespan. Consequently, aging HIV-infected patients face the chronic health conditions and organ failures of the general population. The most important advance in 2 decades is HIV-infected patients with end-stage organ disease being evaluated for and undergoing solid organ transplantation (SOT) [1], now routine clinical care in developed countries and increasingly frequent in developing ones. Multidisciplinary teams including HIV specialists are needed to improve outcomes. So far, we have learned that, first, any organ can be transplanted to HIV-infected patients. Most frequently, it is the kidney, liver and heart, with the pancreas, combined kidney and pancreas and lung transplants also being successful. Second, HIV criteria for SOT have worked [1, 2]. Patients with well-controlled HIV infection on ART, without previous opportunistic infections (OIs) (or with treatable and preventable ones) and meeting minimum CD4+ T cell counts (> 100 for liver and > 200 for other SOT), do not face higher risks of developing OIs after SOT, and HIV-infection remains well controlled. Furthermore, non-boosted integrase inhibitor (e.g., raltegravir and also dolutegravir and bictegravir, although there is less clinical experience) based ARTs [3] have avoided drug-drug interactions with immunosuppressors (e.g., calcineurin inhibitors) and direct antiviral agents (DAAs) for hepatitis C virus (HCV), simplifying the treatment and improving the management and possibly the outcome of this challenging population. Third, dialysis should only be a bridge to kidney transplantation. It has shown its safety and a better prognosis and quality of life for HIV-infected individuals than continued hemodialysis [4]. Fourth, liver transplantation (LT) is a safe and effective therapy for selected HIV-infected patients with hepatocellular carcinoma (HCC) [5], a leading non-AIDS defining cancer in this population. Fifth, acute rejection is more common in SOT HIV-infected recipients and associated with graft loss [6, 7, 8]. The pathophysiology is unknown, and transplant teams must diagnose and treat early. Finally, mid- (5 years) and long-term (10 years) survival rates of kidney, liver and heart transplantation are lower than their matched HIV-negative recipients but are still acceptable (Table 1) (see references in supplementary material). HCV co-infection has negatively affected these results, as the cure rate with pegylated interferon and ribavirin was low. However, interferon-free DAAs have since changed this, and cure rates for LT are high, similar to those in HIV-negative recipients [9]. With HCV eliminated, the prognosis of liver and renal transplantation in HIV-infected patients is good (Table 1). Eliminating HCV is important in liver retransplantation, as the outcomes of HCV-HIV co-infected recipients are poor short term [10]. Table 1 Long-term survival of kidney, liver and heart transplants in HIV-infected recipients compared with HIV-negative controls Type of SOT/country (references) Period Number of patients Years P value 1 2 3 4 5 10 Kidney/USA [1] 2002–2011 HIV+ HCV− (n = 362) 96% – 92% – 89% 64% 0.096 HIV− HCV− (n = 3620) 97% – 94% – 89% 78% Kidney/USA [1] 2002–2011 HIV+ HCV+ (n = 104) 91% – 77% – 67% 29% 0.001 HIV− HCV+ (n = 1050) 94% – 86% – 79% 56% Liver/Spain [2] 2002–2006 HIV+/HCV+ (n = 84) 88% 71% 62% 60% 54% – 0.008 HIV−/HCV+ (n = 252) 90% 81% 76% 73% 71% – Liver/Spain [3] 2002–2009 HIV+/HCV+ SVR (n = 16) 93% 87% 79% 79% 79% – 0.093 HIV−/HCV + SVR (n = 64) 98% 98% 98% 92% 92% – Liver/USA [4] 2002–2011 HIV+/HCV+ (n = 117) 77% – 59% – 52% 44% < 0.001 HIV−/HCV+ (n = 15,581) 88% – 76% – 69% 60% Liver/USA [5] 2001–2007 HIV+/HBV+ (n = 22) 85% – 85% – 85% – 0.090 HIV−/HBV+ (n = 20) 100% – 100% – 100% – Heart/USA [6] 1999–2004 HIV+ (n = 20) 86% – 79% – – – 0.950 HIV− (n = 9174) 90% – 90% – – – Heart/USA [7] 2004–2016 HIV+ (n = 35) 100% – 88% – 88% – 0.149 HIV− (n = 21,400) 89% – 83% – 77% – References are listed in the supplementary material SVR sustained virologic response Many challenges remain, however, particularly combined organ transplantation and small donor organ pools for HIV- and non-HIV-infected patients. Combined kidney-liver transplantation (CKLT) and simultaneous kidney-pancreas transplantation (SKPT) have been reported in HIV-infected patients with contradictory results. The NIH trial [7] of LT in HIV-infected individuals showed CKLT to be associated with poor outcomes. It has therefore been rarely performed with these results negatively impacting decisions by transplant teams. We believe that it should be revisited in the current era. Experience in SKPT in HIV-infected individuals is still limited. A few case reports suggest that it is feasible in individuals with HIV, although outcomes are mixed. In the largest series [11] of four HIV-infected recipients with type 1 diabetes mellitus and end-stage renal disease (ESRD), all patients suffered complications requiring surgical re-exploration and postoperative infections. At a mean follow-up of 45 months, all four had normal renal function, and one experienced late pancreatic graft failure, whereas three remained insulin independent. More data are needed to determine if pancreas transplantation in HIV-infected recipients is safe and feasible. Unfortunately, donor organs are in short supply, whereas waiting lists grow. Using organs from living donors is not well explored in HIV-infected patients, and using organs from HCV-infected or HIV-infected donors is currently being investigated. Living-donor kidney transplantation (KT) is the oldest solid organ transplantation and is associated with better outcome than deceased-donor KT in the general population. However, in a recent publication [12], the likelihood of living-donor KT in HIV-infected candidates has been reported to be 47% lower, with a trend toward lower likelihood of deceased-donor KT. However, in the NIH trial [6] of KT in HIV-infected individuals, using living-donor transplants was protective against graft loss. Therefore, HIV-infected patients with ESRD should not be excluded from living-donor transplant programs. Living-donor liver transplantation (LDLT) has been controversial since its inception because of the significant risks to the living donor, including death and substantial morbidity. For these reasons and because of the initial poor outcomes of LT in HIV/HCV co-infected patients in the pre-DAA era, LDLT in HIV-infected individuals has not been considered so far. We believe that in the current era of ART and DAAs, it should be explored as an alternative to deceased-donor transplantation. The use of deceased HCV+ donors for HCV/HIV co-infected recipients showed inferior results in the NIH trial [7] of LT in HIV-infected individuals. However, it should be reassessed in the future in both LT and KT in HIV-infected recipients because of the good preliminary results in KT in HIV-uninfected individuals, where pre- and post-transplant HCV treatment with DAAs was safe and prevented chronic HCV infection in HCV D+/R− kidney transplant recipients [13]. Another emerging research field is the transplantation of organs from HIV-infected donors to HIV-infected recipients (HIV D+/R+). There are unique risks of HIV D+/R+ transplant to consider [1]. These include donor-to-recipient HIV superinfection, occult OIs in HIV-infected donors or lower organ quality due to the impact of chronic HIV on organ function. These theoretical risks will need to be weighed against the morbidity and mortality of remaining on waiting lists and the survival benefit of transplantation. The practice of HIV D+/R+ KT was pioneered in South Africa by Muller et al. [14] who reported 3- and 5-year patient survival of 84% and 74%, respectively, for 27 HIV D+/R+ kidney transplants. These outcomes are not significantly different from outcomes of HIV+ kidney transplants using HIV-uninfected donors (HIV D−/R+). Furthermore, this series saw neither HIV virologic failure nor AIDS-defining OIs. HIV D+/R+ liver transplant experience is limited to a few case reports without unusual complications. In the USA, federal law banned HIV D+/R+ transplantation in 1984, but it was revised with the HIV Organ Policy Equity (HOPE) Act in 2013, allowing HIV D+/R+ transplants in research trials. Multicenter national trials investigating the practice of HIV D+/R+ deceased-donor kidney and liver transplantation (NCT02602262, NCT03500315) and HIV D+/R+ living donor kidney transplantation (NCT03408106) are underway. In conclusion, the field of SOT in HIV-infected patients is evolving rapidly. As a recent example, a publication reporting the successful LDLT from an HIV-positive to an HIV-negative individual opens a completely new scenario in the setting of SOT in HIV-infected individuals [15]. Notes Acknowledgements JMM received a personal 80:20 research Grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–2019. Funding JMM has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer and ViiV Healthcare; PAG has received consulting honoraria and/or research grants from Angelini, BD, Biotest, Gilead, MSD, Nordic, Paratek, Pfizer and Shire. CMD has received consulting honoraria and/or research grants from Bristol Meyers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Dome & Corp. and ViiV Healthcare. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary material 134_2019_5524_MOESM1_ESM.docx (15 kb) Supplementary material 1 (DOCX 14 kb) References 1. Shaffer AA, Durand CM (2018) Solid organ transplantation for HIV-infected individuals. Curr Treat Options Infect Dis 10:107–120CrossRefGoogle Scholar 2. Miro JM, Torre-Cisnero J, Moreno A et al (2005) GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin 23:353–362CrossRefGoogle Scholar 3. Tricot L, Teicher E, Peytavin G et al (2009) Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 9:1946–1952CrossRefGoogle Scholar 4. Locke JE, Gustafson S, Mehta S et al (2017) Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg 265:604–608CrossRefGoogle Scholar 5. Agüero F, Forner A, Manzardo C et al (2016) Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology 63:488–498CrossRefGoogle Scholar 6. Stock PG, Barin B, Murphy B et al (2010) Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 363:2004–2014CrossRefGoogle Scholar 7. Terrault NA, Roland ME, Schiano T et al (2012) Outcomes of liver transplant recipients with hepatitis C and HIV coinfection. Liver Transpl 18:716–726CrossRefGoogle Scholar 8. Miro JM, Montejo M, Castells L et al (2012) Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 12:1866–1876CrossRefGoogle Scholar 9. Manzardo C, Londoño MC, Castells L et al (2018) Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study. Am J Transplant 18:2513–2522CrossRefGoogle Scholar 10. Agüero F, Rimola A, Stock P et al (2016) Liver retransplantation in patients with HIV-1 infection: an international multicenter cohort study. Am J Transplant 16:679–687CrossRefGoogle Scholar 11. Grossi PA, Righi E, Gasperina DD et al (2012) Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant 12:1039–1045CrossRefGoogle Scholar 12. Locke JE, Mehta S, Sawinski D et al (2017) Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol 12:467–475CrossRefGoogle Scholar 13. Durand CM, Bowring MG, Brown DM et al (2018) Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med 168:533–540CrossRefGoogle Scholar 14. Muller E, Barday Z, Mendelson M, Kahn D (2015) HIV-positive-to-HIV-positive kidney transplantation—results at 3–5 years. N Engl J Med 372:613–620CrossRefGoogle Scholar 15. Botha J, Conradie F, Etheredge H et al (2018) Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options. AIDS 32:F13–F19CrossRefGoogle Scholar Copyright information © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Authors and Affiliations Jose M. Miro1Email authorPaolo A. Grossi2Christine M. Durand31.Infectious Diseases ServiceHospital Clinic - IDIBAPS, University of BarcelonaBarcelonaSpain2.Infectious and Tropical Diseases Unit, Department of Medicine and SurgeryUniversity of InsubriaVareseItaly3.Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA

This is a preview of a remote PDF:

Jose M. Miro, Paolo A. Grossi, Christine M. Durand. Challenges in solid organ transplantation in people living with HIV, Intensive Care Medicine, 2019, 1-3, DOI: 10.1007/s00134-019-05524-1